title: Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
abstract: The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.
authors: Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
authors: Aiko
authors: A
authors: Ishihara
authors: Takafumi
authors: T
authors: Miyachi
authors: Takeshi
authors: T
authors: Nakamura
authors: Toshiho
authors: T
authors: Ohtsuki
authors: Yasuhiro
authors: Y
authors: Kimura
authors: Kenji
authors: K
authors: Kihira
authors: Takemori
authors: T
authors: Yamawaki
authors: Masayasu
authors: M
authors: Matsumoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002230:Carbidopa / Q000627:therapeutic use; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000627:therapeutic use*; D018450:Disease Progression; D004296:Dopa Decarboxylase / Q000378:metabolism; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007564:Japan; D007980:Levodopa / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009570:Nitriles / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D011446:Prospective Studies; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000978:Antiparkinson Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D015415:Biomarkers; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D014443:Tyrosine; D007980:Levodopa; C071192:entacapone; D001545:Benserazide; D002394:Catechol O-Methyltransferase; D004296:Dopa Decarboxylase; D002230:Carbidopa; C008404:3-methoxytyrosine